Objective-Sterol regulatory element-binding protein-1 (SREBP-1) is nutritionally regulated and is known to be a key transcription factor regulating lipogenic enzymes. The goal of this study was to evaluate the roles of SREBP-1 in dyslipidemia and atherosclerosis. Methods and Results-Transgenic mice that overexpress SREBP-1c in the liver and SREBP-1-deficient mice were crossed with low-density lipoprotein receptor (LDLR)-deficient mice, and the plasma lipids and atherosclerosis were analyzed. Hepatic SREBP-1c overexpression in LDLR-deficient mice caused postprandial hypertriglyceridemia, increased very-low-density lipoprotein (VLDL) cholesterol, and decreased high-density lipoprotein cholesterol in plasma, which resulted in accelerated aortic atheroma formation. Conversely, absence of SREBP-1 suppressed Western diet-induced hyperlipidemia in LDLR-deficient mice and ameliorated atherosclerosis. In contrast, bone marrow-specific SREBP-1 deficiency did not alter the development of atherosclerosis. The size of nascent VLDL particles secreted from the liver was increased in SREBP-1c transgenic mice and reduced in SREBP-1-deficient mice, accompanied by upregulation and downregulation of phospholipid transfer protein expression, respectively.
S terol regulatory element-binding proteins (SREBPs) are transcription factors that belong to the basic helix-loophelix leucine zipper family. 1, 2 Unlike other basic helix-loophelix leucine zipper family transcription factors, SREBPs are synthesized as membrane-bound precursors and embedded in the endoplasmic reticulum membrane. There, they form a complex with SREBP cleavage-activating protein. When cellular cholesterol levels are depleted, SREBP cleavageactivating protein escorts SREBPs to the Golgi apparatus, where SREBPs are cleaved by site-1 and site-2 proteases. After cleavage, SREBPs transfer to the nucleus and activate enzymes involved in lipid synthesis. The SREBP family consists of 3 isoforms: SREBP-1a, SREBP-1c, and SREBP-2. SREBP-1a and SREBP-1c are derived from a single gene through the use of alternative promoters. SREBP-1a has a potent transcriptional activity for genes involved in synthesis of cholesterol, fatty acids, and triglycerides (TGs). 3 In contrast, SREBP-1c has a transcriptional activity for genes involved in fatty acid and TG synthesis. 4,5 SREBP-2 selectively activates transcription of genes involved in cholesterol synthesis. 6 Unlike SREBP-1a, SREBP-1c is regulated by nutritional conditions and therefore plays a central role in nutritional regulation of lipogenesis as a dominant isoform in liver and adipose tissues. 7 Whereas SREBP-1c levels are low in fasting states, they are dramatically increased in refed states in response to higher levels of glucose and insulin. 8 -10 Owing to its activation by overnutrition, SREBP-1c could be the cause of several metabolic disorders. Previous studies revealed that SREBP-1 is involved in hepatic steatosis and insulin resistance. 11, 12 Because SREBP-1c is activated in the hyperglycemic or hyperinsulinemic state, it may contribute to diabetes-associated dyslipidemia and progression of atherosclerosis. Although the impact of SREBP-1c on the expression of lipogenic enzyme genes is well established, how SREBP-1c affects plasma lipoprotein metabolism is poorly understood. In addition, the contribution of endogenous SREBP-1 to progression of dyslipidemia and atherosclerosis is still unclear. To investigate the role of SREBP-1 in lipoprotein metabolism and development of atherosclerosis, we generated low-density lipoprotein receptor-deficient (LDLR Ϫ/Ϫ ) mouse models that either overexpress SREBP-1c in the liver or lack SREBP-1.
Materials and Methods

Mice
This project was approved and performed under the guidelines of the Animal Care Committee of the University of Tsukuba. Transgenic mice overexpressing amino acids 1 to 436 of human SREBP-1c under control of the phosphoenolpyruvate carboxykinase promoter on a C57BL/6J background (hereafter referred to as TgBP-1c) were generated as previously described. 4 The TgBP-1c mice were crossed with LDLR Ϫ/Ϫ mice 13 to produce TgBP-1cLDLR Ϫ/Ϫ mice. SREBP-1deficient mice (SREBP-1 Ϫ/Ϫ ) 14 
High-Performance Liquid Chromatography Analysis
For the lipoprotein distribution analysis, pooled plasma samples from 4 to 5 mice per group were analyzed by an upgraded high-performance liquid chromatography (HPLC) technique as previously described (Skylight Biotech). 15
Isolation of Very-Low-Density Lipoprotein Faction and Western Blot
Very-low-density lipoprotein (VLDL) (dϽ1.006 g/mL) fraction was isolated by ultracentrifugation using TLA120.2 rotor (Beckman Coulter). The VLDL fractions were separated by SDS-PAGE and subject to Coomassie Brilliant Blue staining or Western blot analysis using anti-apolipoprotein B (ApoB) antibody (sc-12332, Santa Cruz). Levels of ApoB100 and ApoB48 were semiquantified using National Institutes of Health ImageJ software, version 1.41 (http://rsb.info.nih.gov/ij/).
Atherosclerotic Lesion Analysis
LDLR Ϫ/Ϫ and littermate TgBP-1cLDLR Ϫ/Ϫ mice were maintained on normal rodent chow until 24 weeks of age. Eight-week-old LDLR Ϫ/Ϫ mice and SREBP-1 Ϫ/Ϫ LDLR Ϫ/Ϫ mice were fed a Western diet (D12079B [34% sucrose, 21% fat, 0.15% cholesterol], Research Diet) for 10 weeks. The mice were then euthanized, and their hearts and aortas were isolated. The hearts were fixed in 4% formalin for more than 48 hours. The basal half of each heart was embedded in Tissue-Tek OCT compound (Sakura Finetek). Crosssections were stained with Oil Red O and hematoxylin. The aorta was cut open along the midline from the iliac arteries to the aortic root. The aorta was pinned out flat, and the lesions were stained with Sudan IV for 15 minutes, destained with 70% ethanol, and then fixed in 4% phosphate-buffered formalin. The atherosclerotic lesions were quantified using Photoshop CS software (Adobe Systems Inc).
TG Production
Mice fasted for the indicated times were injected with Triton WR-1339 (0.5 mg/g body weight, Sigma-Aldrich) via the tail veins to block the clearance of nascent ApoB-containing lipoproteins. Blood samples were collected at 0, 30, 60, and 120 minutes after the injection.
Electron Microscopy of Plasma VLDL
The isolated VLDL fraction was negatively stained with phosphotungstic acid (pH 7) for 2 minutes. The specimen was viewed under a JEM-1400 electron microscope (JEOL). The mean diameters of the VLDL particles were determined using ImageJ software version 1.41.
Results
Hepatic SREBP-1c Activation Induces Atherogenic Lipoprotein Profiles in LDLR ؊/؊ Mice
To investigate whether hepatic SREBP-1c overexpression alters plasma lipoprotein profiles, we crossed TgBP-1c mice with LDLR Ϫ/Ϫ mice (TgBP-1cLDLR Ϫ/Ϫ ). First, the metabolic characteristics were investigated. TgBP-1cLDLR Ϫ/Ϫ mice exhibited higher plasma cholesterol levels than did LDLR Ϫ/Ϫ mice in both the fasted and refed states (1.3-fold and 1.4-fold, respectively; Figure 1 A, top). Plasma TG levels were 2.6-fold higher in the refed TgBP-1cLDLR Ϫ/Ϫ mice than in the refed LDLR Ϫ/Ϫ mice ( Figure 1A , bottom). The elevated plasma cholesterol levels were also observed in the presence of LDLR (Supplemental Figure IA , available online at http://atvb.ahajournals.org). Plasma HPLC analysis revealed that VLDL and remnant cholesterol levels were higher in the TgBP-1cLDLR Ϫ/Ϫ mice than in the LDLR Ϫ/Ϫ mice ( Figure  1B) . Interestingly, the marked VLDL-TG elevation and high-density lipoprotein cholesterol reduction were observed only in the refed TgBP-1cLDLR Ϫ/Ϫ mice. To validate these results, the VLDL fraction was isolated by ultracentrifugation. In agreement with the HPLC analysis, VLDL cholesterol levels were higher in both the fasted and refed TgBP-1cLDLR Ϫ/Ϫ mice than in the LDLR Ϫ/Ϫ mice (1.9-fold in the fasted state and 3.1-fold in the refed state; Figure 1C ). Elevation of the VLDL-TG levels in TgBP-1cLDLR Ϫ/Ϫ mice was prominent in the refed state but not in the fasted state. The VLDL fraction was analyzed by SDS-PAGE ( Figure  1D ). ApoB100 protein exhibited similar levels between TgBP-1cLDLR Ϫ/Ϫ mice and LDLR Ϫ/Ϫ controls in either the fasted or the refed state, whereas ApoB48 was 2-fold higher in the refed state. Liver TG and cholesterol contents were significantly higher in the refed TgBP-1cLDLR Ϫ/Ϫ mice than in the refed LDLR Ϫ/Ϫ mice ( Supplemental Table I ). These data indicated that activation of hepatic SREBP-1c induced accumulation of postprandial remnant lipoprotein rich in both the cholesterol and the TGs. Plasma glucose and insulin levels in the TgBP-1cLDLR Ϫ/Ϫ mice were not significantly changed as compared with the LDLR Ϫ/Ϫ mice in both the fasted and refed states. However, TgBP-1c LDLR Ϫ/Ϫ mice exhibited impaired glucose tolerance and mild insulin resistance compared with LDLR Ϫ/Ϫ mice (Supplemental Figure II) .
Hepatic SREBP-1c Activation Accelerates Atherosclerosis in LDLR ؊/؊ Mice
To determine the effect of hepatic SREBP-1c activation on atherosclerosis in LDLR Ϫ/Ϫ mice, we examined atheroscle-rotic lesion formation in the proximal aorta of 24-week-old mice fed normal chow. The lesions stained with Oil Red O were 2.4-fold higher in the TgBP-1cLDLR Ϫ/Ϫ mice than in the LDLR Ϫ/Ϫ mice (Figure 2A and 2B).
Systemic SREBP-1 Deficiency Improves Atherogenic Lipoprotein Profiles in LDLR ؊/؊ Mice
To investigate whether systemic SREBP-1 deficiency improves lipoprotein profiles and atherosclerotic lesion formation, we next generated SREBP-1 Ϫ/Ϫ LDLR Ϫ/Ϫ mice. In the mice given normal chow, plasma total cholesterol levels did not significantly change in the male LDLR Ϫ/Ϫ and SREBP-1 Ϫ/Ϫ LDLR Ϫ/Ϫ mice, but plasma TG levels were lower in the SREBP-1 Ϫ/Ϫ LDLR Ϫ/Ϫ mice than in the LDLR Ϫ/Ϫ mice (127Ϯ7 mg/dL versus 76Ϯ5 mg/dL; Figure 3A ). The mice were placed on a Western diet for 4 weeks, and the plasma lipid profiles were then analyzed. In the LDLR Ϫ/Ϫ mice, the plasma cholesterol levels were elevated to more than 1000 mg/dL, and the TG levels were also elevated to Ϸ590 mg/dL. In the SREBP-1 Ϫ/Ϫ LDLR Ϫ/Ϫ mice, plasma cholesterol was only 67% that of the LDLR Ϫ/Ϫ mice ( Figure 3A ). Furthermore, plasma TG levels were dramatically lower (71%) in the SREBP-1 Ϫ/Ϫ LDLR Ϫ/Ϫ mice than in the LDLR Ϫ/Ϫ mice.
Analysis by high-performance liquid chromatography revealed a marked reduction of cholesterol in the chylomicrons and VLDL of the SREBP-1 Ϫ/Ϫ LDLR Ϫ/Ϫ mice compared with that in the LDLR Ϫ/Ϫ mice ( Figure 3B , top). Furthermore, TG levels in the SREBP-1 Ϫ/Ϫ LDLR Ϫ/Ϫ mice were lower than those in the LDLR Ϫ/Ϫ mice in all lipoprotein subclasses ( Figure 3B , bottom). Hypolipidemic effects of SREBP-1 deficiency were also observed in the LDLR ϩ/ϩ background (Supplemental Figure  IB) . To evaluate VLDL lipid composition and ApoB levels, plasma lipoprotein was separated by ultracentrifugation. In accordance with the HPLC analysis, VLDL-TG, VLDL cholesterol, and VLDL-phospholipids in the SREBP-1 Ϫ/Ϫ LDLR Ϫ/Ϫ mice were markedly lower (86%, 84%, and 73%, respectively) than those in the LDLR Ϫ/Ϫ mice ( Figure 3C ). VLDL ApoB100 levels in the SREBP-1 Ϫ/Ϫ LDLR Ϫ/Ϫ mice decreased to 50% of those in the LDLR Ϫ/Ϫ mice, and ApoB48 levels in the SREBP-1 Ϫ/Ϫ LDLR Ϫ/Ϫ mice decreased more markedly, to 10% of those in the LDLR Ϫ/Ϫ mice ( Figure 3D ). Liver TG and cholesterol contents were not significantly changed in the LDLR Ϫ/Ϫ and SREBP-1 Ϫ/Ϫ LDLR Ϫ/Ϫ mice ( Supplemental Table II ). To determine whether hypolipidemic phenotype in SREBP-1 Ϫ/Ϫ LDLR Ϫ/Ϫ mice was due to the hepatic SREBP-1 deficiency, we attempted restoration of SREBP-1c by 
Systemic SREBP-1 Deficiency Reduces Atherosclerotic Lesion Formation in LDLR ؊/؊ Mice
LDLR Ϫ/Ϫ and SREBP-1 Ϫ/Ϫ LDLR Ϫ/Ϫ mice fed a Western diet for 10 weeks were subjected to atherosclerosis analysis in both cross-sections of the proximal aorta and pinned-out en face aorta. Analysis of the proximal aorta revealed that lesion formation in the male SREBP-1 Ϫ/Ϫ LDLR Ϫ/Ϫ mice was significantly suppressed by 71% of that of LDLR Ϫ/Ϫ mice ( Figure 4A and 4B). The lesion area in the whole aorta stained with Sudan IV was 40% lower in the male SREBP-1 Ϫ/Ϫ LDLR Ϫ/Ϫ mice than in the male LDLR Ϫ/Ϫ mice ( Figure 4C and 4D) . For further investigation, gene expression analysis was also performed to characterize the aortic lesion. Real-time reverse transcription-polymerase chain reaction analysis revealed that interleukin-6 expression in the SREBP-1 Ϫ/Ϫ LDLR Ϫ/Ϫ mice was lower than in the LDLR Ϫ/Ϫ mice, whereas CD68 and Emr1 expression was unchanged (Supplemental Figure IV) . These results suggest that atherosclerosis development was attenuated in SREBP-1 Ϫ/Ϫ LDLR Ϫ/Ϫ mice. of genes involving cholesterol efflux or modified lipoprotein uptake were similar in the SREBP-1 ϩ/ϩ MPM and SREBP-1 Ϫ/Ϫ MPM (Supplemental Figure VIC and VID) . Collectively, SREBP-1 deficiency in macrophages did not prevent accumulation of cholesterol either in vivo or in vitro.
Macrophage SREBP-1 Deficiency Does Not Reduce Atherosclerotic Lesion Formation in LDLR ؊/؊ Mice
Hepatic SREBP-1c Activation Enlarges Nascent VLDL Particle Size
To investigate how hepatic SREBP-1c regulates plasma lipoprotein profiles, plasma TG production was evaluated in TgBP-1cLDLR Ϫ/Ϫ mice. After being fasted for 24 hours, LDLR Ϫ/Ϫ and TgBP-1cLDLR Ϫ/Ϫ mice were injected with Triton WR-1339 to block ApoB lipoprotein clearance. Although TG production rates were similar in the LDLR Ϫ/Ϫ and TgBP-1cLDLR Ϫ/Ϫ mice ( Figure 5A ), only plasma from the TgBP-1cLDLR Ϫ/Ϫ mice became milky. To characterize the secreted lipoproteins, VLDL fractions were isolated from plasma after Triton WR-1339 injection and analyzed by electron microscopy. Larger particles were prominent in the nascent VLDL fraction from TgBP-1cLDLR Ϫ/Ϫ mice than in that from LDLR Ϫ/Ϫ mice ( Figure 5B ). Even on a LDLR ϩ/ϩ background, larger particles were observed in the nascent VLDL fraction from TgBP-1c mice ( Figure 5C ). Consequently, the average diameter of the nascent VLDL particles observed at fasting was 1.3-fold higher and the volume of the particles was 2.9-fold higher in the TgBP-1c mice than in the wild-type (WT) mice. Because TgBP-1cLDLR Ϫ/Ϫ mice exhibited higher plasma TG levels in the refed state, TG production after feeding was also examined. TG production rate after refeeding in TgBP-1cLDLR Ϫ/Ϫ mice was greater than in LDLR Ϫ/Ϫ mice (Supplemental Figure VIIA) . Meanwhile, lipase activity and postprandial plasma TG response examined by oral fat load test was not changed between LDLR Ϫ/Ϫ mice and TgBP-1cLDLR Ϫ/Ϫ mice (Supplemental Figure VIIB and VIIC) . These data indicated that production of large VLDL particles causes atherogenic lipoprotein profiles in TgBP-1cLDLR Ϫ/Ϫ mice.
Hepatic SREBP-1c Activation Increases Phospholipid Transfer Protein Expression
The hepatic gene expression profiles demonstrated that in agreement with the increased nuclear SREBP-1 level, lipogenic genes, such as fatty acid synthase, stearoyl-coenzyme A desaturase-1, and glycerol-3-phosphate acyltransferase mitochondrial, were elevated in TgBP-1cLDLR Ϫ/Ϫ mice (Supplemental Figure VIIIA and VIIIB). To define the genes responsible for the enlarged nascent VLDLs, genes involved in TG synthesis and secretion were also examined ( Figure  5D ). Expressions of diacylglycerol O-acyltransferase 1 and 2 were unchanged in TgBP-1cLDLR Ϫ/Ϫ mice. Furthermore, neither microsomal TG transfer protein, known to be rate limiting for VLDL assembly, nor ApoB was increased. On the other hand, phospholipid transfer protein (PLTP), which participates in lipid transfer among plasma lipoproteins and promotes VLDL secretion, 16,17 exhibited a 5.9-fold increase as compared with the LDLR Ϫ/Ϫ mice. Expression of lipoprotein lipase in both the liver and the adipose tissue, as well as of hepatic lipase, was not decreased (Supplemental Figure  VIIIC) .
Systemic SREBP-1 Deficiency Reduces the Size of Nascent VLDL Particles
Consistent with the marked reduction in plasma TGs, the rates of TG secretion from SREBP-1 Ϫ/Ϫ LDLR Ϫ/Ϫ mice were 28% lower than those in LDLR Ϫ/Ϫ mice at 120 minutes after the Triton WR-1339 injection ( Figure 6A ). The size of nascent VLDL particles secreted from SREBP-1 Ϫ/Ϫ mice fed a Western diet for 4 weeks was apparently smaller than that in WT mice ( Figure 6B ). The average diameter and volume of the particles were reduced in SREBP-1 Ϫ/Ϫ mice. Northern blot analysis revealed truncated SREBP-1 expression and decreased lipogenic enzymes, such as fatty acid synthase, stearoyl-coenzyme A desaturase-1, and glycerol-3-phosphate acyltransferase mitochondrial, in the liver of SREBP-1 Ϫ/Ϫ LDLR Ϫ/Ϫ mice (Supplemental Figure IXA ). Real-time polymerase chain reaction analysis revealed that diacylglycerol O-acyltransferase 1 and 2 expressions were unchanged ( Figure 6C ). In addition, expression of both ApoB and microsomal TG transfer protein was not decreased in SREBP-1 Ϫ/Ϫ LDLR Ϫ/Ϫ mice. Importantly, PLTP expression was 47% lower in the SREBP-1 Ϫ/Ϫ LDLR Ϫ/Ϫ mice than in the LDLR Ϫ/Ϫ mice. In addition, adenoviral-mediated SREBP-1c transfer caused PLTP expression level in the SREBP-1 Ϫ/Ϫ LDLR Ϫ/Ϫ mice to revert to the level in the LDLR Ϫ/Ϫ mice (Supplemental Figure IIIF) . We also examined the expression of lipases in the liver and white adipose tissue. Lipoprotein lipase expression was lower in both the liver and the adipose tissue from SREBP-1 Ϫ/Ϫ LDLR Ϫ/Ϫ mice (Supplemental Figure IXB) and plasma lipase activity was lower in the SREBP-1 Ϫ/Ϫ LDLR Ϫ/Ϫ mice than in the LDLR Ϫ/Ϫ mice (Supplemental Figure IXC) . These data suggest that plasma TG clearance cannot account for the reduced plasma TGs in SREBP-1 Ϫ/Ϫ LDLR Ϫ/Ϫ mice.
Discussion
Our current study clearly demonstrates that hepatic SREBP-1c plays a determinant role in levels of plasma TGs and remnant cholesterol and contributes to atherosclerosis in hyperlipidemic models. Overexpression of hepatic SREBP-1c causes dyslipidemia and accelerates aortic atheroma formation in LDLR Ϫ/Ϫ mice. Dyslipidemia in TgBP-1cLDLR Ϫ/Ϫ mice was characterized by postprandial elevation of remnant cholesterol and TG and reduction of high-density lipoprotein cholesterol, making this animal a good atherogenic model of postprandial hyperlipidemia and impaired glucose tolerance. Overproduction of lipidrich large VLDL is a hallmark of dyslipidemia in type 2 diabetes and insulin resistance, 18 and SREBP-1c activation could be involved in this process. Meanwhile, SREBP-1 deficiency attenuated diet-induced hyperlipidemia and atherosclerosis progression in LDLR Ϫ/Ϫ mice. In contrast, macrophage-specific SREBP-1 deficiency had no effect on atherosclerosis development in LDLR Ϫ/Ϫ mice. Taken together with the observation that the hypolipidemic phenotype in SREBP-1 Ϫ/Ϫ LDLR Ϫ/Ϫ mice was abolished by hepatic SREBP-1c overexpression, these results suggest that suppression of atherosclerosis in SREBP-1 Ϫ/Ϫ LDLR Ϫ/Ϫ mice is due mainly to altered plasma lipoprotein profiles as a consequence of the absence of hepatic SREBP-1 Figure 5 . Characterization of VLDL production and lipoprotein metabolism in SREBP-1c transgenic mice. A, TG production rates in LDLR Ϫ/Ϫ and TgBP-1cLDLR Ϫ/Ϫ mice. LDLR Ϫ/Ϫ and TgBP-1cLDLR Ϫ/Ϫ mice fasted for 24 hours were injected with Triton WR-1339 via the tail vein (nϭ5). Plasma was collected at 0, 30, 60, and 120 minutes after injection with Triton WR-1339. Plasma obtained at 120 minutes was used for ultracentrifugation to isolate the VLDL fraction. B, Electron microscopic image of secreted VLDL particles from LDLR Ϫ/Ϫ and TgBP-1cLDLR Ϫ/Ϫ mice. Isolated VLDL was negatively stained with phosphotungstic acid and visualized by electron microscopy. C, Particle size analysis of nascent VLDL from WT and TgBP-1c mice. WT and TgBP-1c mice fasted for 24 hours were injected with Triton WR-1339 via the tail vein (nϭ4). Isolated VLDL particles were visualized by electron microscopy. Three hundred VLDL particles were randomly selected from each mouse and the diameters of VLDL particles were measured using ImageJ software. The VLDL particle volume was calculated on the basis of the particles as entire spheres. D, Gene expression analysis of LDLR Ϫ/Ϫ and TgBP-1cLDLR Ϫ/Ϫ mice. The livers were collected from 8-week-old LDLR Ϫ/Ϫ and TgBP-1cLDLR Ϫ/Ϫ mice after they were fasted for 24 hours (nϭ5). Gene expressions were analyzed using reverse transcription-polymerase chain reaction. MTP indicates microsomal TG transfer protein. Values are shown as meanϮSEM. *PϽ0.05, **PϽ0.01, ***PϽ0.005 vs control. Similar results were obtained from 2 independent experiments. CIDEB indicates cell death-inducing DIVA fragmentation factor, alpha subunit-like effector B. and that SREBP-1 in macrophages have less influence on the development of atherosclerosis.
One of the most remarkable changes in altered lipoprotein profiles by hepatic SREBP-1c activation was increased large plasma VLDL and remnant lipoproteins. The large VLDL seemed to be a resource of remnant lipoproteins through the lipolysis process. These changes were inversely suppressed in the SREBP-1 Ϫ/Ϫ LDLR Ϫ/Ϫ mice fed a Western diet. Therefore it is suggested that SREBP-1 determines plasma remnant lipoprotein level and consequent atherosclerosis development.
In relation to this issue, another novel finding in our models is that hepatic SREBP-1c controls the size of nascent VLDL particles. Liver X receptor is also known to be a transcription factor that regulates SREBP-1c and VLDL particle size. 19 -21 A recent report revealed that massive hyperlipidemia with large VLDL particle formation by pharmacological liver X receptor activation was diminished in SREBP-1c-deficient LDLR Ϫ/Ϫ mice. 22 Moreover, this response to the liver X receptor agonist was partially rescued by adenoviral PLTP overexpression, indicating the importance of liver X receptor-SREBP-1c-PLTP axis in the VLDL particle size. It has been shown that PLTP accelerates atherosclerosis development by promoting ApoB production. 17, 23 Our data from models with SREBP-1-transgenic and -deficient mice are also associated with the changes in PLTP expression consistent with these observations. Although it is currently unknown whether SREBP-1c directly activates PLTP and accelerates lipidation of VLDL, PLTP plays a key role in plasma lipoprotein profiles. Meanwhile, it is also possible that SREBP-1c might activate one or more other genes involved in lipidation of VLDL particles in the liver. Recently, it has been recognized that VLDL maturation in the liver comprises 2 steps: large VLDL, called VLDL1, seemed to be generated as a consequence of bulk lipidation of VLDL2. 24 -26 Although little is known about the genes responsible for VLDL lipidation, it is intriguing to speculate that SREBP-1 regulates these unknown genes. A previous study reported that the lipid droplet-associated protein cell death-inducing DIVA fragmentation factor, alpha subunit-like effector B promotes VLDL lipidation by interacting with ApoB, 27 but in our models, the cell deathinducing DIVA fragmentation factor, alpha subunit-like effector B expression was unchanged.
In summary, we have shown that hepatic SREBP-1c controls plasma TG-rich lipoproteins and atherosclerosis. The altered lipoprotein profiles are partially due to production of large VLDL particles. Because SREBP-1c is elevated in insulin resistance and type 2 diabetes, it might play a central Figure 6 . Characterization of VLDL production and lipoprotein metabolism in SREBP-1-deficient mice. A, TG production rates in LDLR Ϫ/Ϫ and SREBP-1 Ϫ/Ϫ LDLR Ϫ/Ϫ mice. LDLR Ϫ/Ϫ and SREBP-1 Ϫ/Ϫ LDLR Ϫ/Ϫ mice fed a Western diet for 4 weeks were injected with Triton WR-1339 via the tail vein after they were fasted for 5 hours (nϭ4). Plasma was collected at 0, 30, 60, and 120 minutes after the Triton WR-1339 injection. B, Particle size analysis of nascent VLDL from WT and SREBP-1-deficient mice. WT and SREBP-1 Ϫ/Ϫ mice fed a Western diet for 4 weeks were injected with Triton WR-1339 after they were fasted for 5 hours (nϭ3). Isolated VLDL particles were visualized by electron microscopy. Three hundred VLDL particles were randomly selected from each mouse, and the diameters of VLDL particles were measured using ImageJ software. C, Hepatic mRNA expression analysis of LDLR Ϫ/Ϫ and SREBP-1 Ϫ/Ϫ LDLR Ϫ/Ϫ mice. The livers were collected from LDLR Ϫ/Ϫ and SREBP-1 Ϫ/Ϫ mice (nϭ10 to 12) fed a Western diet for 10 weeks and then fasted for 5 hours. Gene expressions were analyzed using reverse transcription-polymerase chain reaction. 
